David A. Siegel Arcturus Therapeutics Holdings Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$27.88 - $58.25 $8.93 Million - $18.7 Million	-320,343 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$25.79 - $42.11 $1.24 Million - $2.02 Million	48,000 Added 17.62%	320,343 $10.8 Million
Q1 2021 May 17, 2021	BUY	$38.75 - $86.92 $3.75 Million - $8.41 Million	96,700 Added 55.05%	272,343 $11.2 Million
Q4 2020 Feb 16, 2021	BUY	$34.61 - $123.66 $616,058 - $2.2 Million	17,800 Added 11.28%	175,643 $7.62 Million
Q3 2020 Nov 16, 2020	BUY	$37.49 - $63.19 $1.82 Million - $3.07 Million	48,600 Added 44.49%	157,843 $6.77 Million
Q2 2020 Aug 14, 2020	BUY	$12.66 - $58.27 $763,398 - $3.51 Million	60,300 Added 123.2%	109,243 $5.11 Million
Q1 2020 May 15, 2020	SELL	$9.31 - $18.26 $931 - $1,826	-100 Reduced 0.2%	48,943 $665,000
Q4 2019 Feb 14, 2020	BUY	$8.93 - $12.41 $437,953 - $608,623	49,043 New	49,043 $533,000

179

25.6M

195K

133K

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $449M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.